Dibenzepin

Oral
Depression

Recent MI, arrhythmias, severe liver disease, manic phase.

CV disease, history of epilepsy, hepatic impairment, hyperthyroidism, pheochromocytoma, history of mania, psychoses, urinary retention, close-angle glaucoma, concurrent electroconvulsive therapy, diabetes. Pregnancy and lactation, elderly, childn. Porphyria. Avoid abrupt withdrawal. May impair ability to drive.

Symptoms: lethargy, drowsiness, nausea, vomiting, and epigastric pain, GI bleeding. Hypertension, acute renal failure, respiratory depression, anaphylactoid reactions and coma may occur rarely. Management: treatment in symptomatic and supportive. There are no specific antidotes. Emesis and/or activated charcoal and/or osmotic cathartic may be reduce drug absorption if present within 4 hr of ingestion. Forced diuresis, alkalinization of urine, haemodialysis, or haemoperfusion unlikely to be useful.

Effects may be enhanced by concomitant use of cimetidine, diltiazem, disulfiram, methylphenidate, ritonavir and verapamil and reduced when used with carbamazepine, rifampicin and oestrogens. Side-effects may be increased by adrenaline, amiodarone, general anaesthetics, SSRIs, anithistamines, antimuscarinics, antipsychotics, anxiolytics and hypnotics, disopyramide, diuretics, flecainide, MAOIs, moclobemide, moxifloxacin, nefopam, nicorandil, noradrenaline, pimozide, procainamide, propafenone, quinidine, selegiline, sibutramine, sotalol, terfenadine, thioridazine and tramadol. Effects of adrenergic neuron blocker, clonidine, barbiturates, nitrates, and primidone are reduced while effects of baclofen, opioid analgesics and thyroid hormones are enhanced.
Potentially Fatal: Concomitant use with brimonidine, entacapone, artemether with lumefantrine should be avoided.

Abnormal liver function test.

Description:
Mechanism of Action: Dibenzepin is a tricyclic antidepressant.

Antidepressants